NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new 10-gene signature, GSLA10, identifies high-risk luminal A breast cancer patients. This discovery aids personalized treatment by predicting recurrence risk and improving patient outcomes.
Area Of Science
- Oncology
- Genetics
- Molecular Biology
Background
- Luminal A breast cancer has a favorable prognosis but a high 10-year recurrence risk.
- Early and late recurrences require different treatment strategies.
- Identifying patients at high risk for recurrence is crucial for effective treatment.
Purpose Of The Study
- To investigate the role of non-structural chromosome maintenance condensin I complex subunit H (NCAPH) in luminal A breast cancer.
- To identify an intratumoural gene expression signature associated with elevated NCAPH levels as a marker for unfavorable progression.
- To develop a predictive tool for patient risk stratification.
Main Methods
- In vitro and in vivo studies using transgenic mouse models overexpressing NCAPH.
- Analysis of a genetically diverse mouse cohort.
- Least absolute shrinkage and selection operator (LASSO) multivariate regression analysis on transcripts associated with elevated NCAPH.
- Derivation of a 10-gene risk score (GSLA10).
Main Results
- Elevated NCAPH levels correlate with adverse luminal A breast cancer progression.
- A 10-gene signature (GSLA10) was developed, associated with unfavorable progression.
- GSLA10 outperformed the Oncotype DX signature in identifying high-risk tumors across independent human cohorts.
- High intratumoural Ncaph levels correlated with worse outcomes and poor chemotherapy response.
Conclusions
- The GSLA10 signature is a promising tool for identifying luminal A breast cancer patients with adverse prognosis.
- This signature can aid in developing personalized treatment strategies.
- Improved patient outcomes are anticipated through better risk stratification and tailored therapies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...